Thermo Fisher Expands Presence in India

Tuesday, December 9, 2008 11:50 AM

Global laboratory supply giant Thermo Fisher opened a new $17 million clinical services facility in Ahmedabad, India, giving the Waltham, Mass.-based company the largest Indian presence of any company in its industry, according to a company release.

The new 150,000-square-foot facility will support growing demand for biopharma services in the region and serve as a hub for packaging, distribution and logistics management of clinical trial supplies.

“With the added capacity now available to us with this new facility, we can offer our customers a higher level of technology, quality and expertise to facilitate clinical trials that serve the needs of both local and multi-national pharmaceutical companies,” said Thermo Fisher president and CEO Marijn Dekkers at the opening of the new facility.

Thermo Fisher first located in India in 2000 and has rapidly expanded its presence there through new facilities and acquisitions. Earlier this year, the company acquired the analytical technologies and environmental instrumentation divisions of Mumbai-based Chemito, India’s largest local supplier of analytical instruments for life sciences and environmental monitoring applications.

Thermo Fisher now has more than 20 facilities and 600 employees in India.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs